Community Research and Development Information Service - CORDIS

FP5

HOLOTC, EARLY B12 MA Report Summary

Project ID: QLK3-CT-2002-01775
Funded under: FP5-LIFE QUALITY
Country: Denmark

Guidelines

Guidelines for the evaluation of the technical performance of the holoTC assay were published together with information on sample handling and determinants of holoTC.

Use of holoTC is simple and does not require either special sample collection or post-treatment. Neither is it, in contrast to the metabolic markers methylmalonic acid or homocysteine, more than marginally influenced by kidney function or age of the patient.

HoloTC is a better marker than is plasma vitamin B12 in identifying persons with vitamin B12 deficiency, as defined by an increased level of MMA. In addition holoTC has the advantage of being easily standardized. This in contrast to total plasma vitamin B12, where a lack of standardisation requires laboratories to implement their own reference ranges and cut-off values. Further guidelines as to the use of holoTC are to be published in papers now in progress.

Contact

Ebba NEXO, (Professor)
Tel.: +45-89-493083
Fax: +45-89-493060
E-mail
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top